• insulin
  • In addition, the majority of diabetic patients are overweight or obese, and many of the current therapies are associated with weight gain, which causes insulin resistance and deterioration in glycemic control ( 2 ). (diabetesjournals.org)
  • Diabetes mellitus type 2 is a disease of insulin resistance by cells. (wikipedia.org)
  • Treatments include (1) agents that increase the amount of insulin secreted by the pancreas, (2) agents that increase the sensitivity of target organs to insulin, and (3) agents that decrease the rate at which glucose is absorbed from the gastrointestinal tract. (wikipedia.org)
  • urine
  • Because of SGLT2 action, most people have no measurable glucose in their urine. (diabetesselfmanagement.com)
  • Every day approximately 180 grams of glucose are filtered through the glomeruli and lost into the primary urine in healthy adults, but more than 90% of the glucose that is initially filtered is reabsorbed by a high capacity system controlled by SGLT-2 in the early convoluted segment of the proximal tubules. (wikipedia.org)
  • metformin
  • Their subjects, 1,450 in total, were all diagnosed with type 2 diabetes and were currently taking metformin. (battlediabetes.com)
  • Although it must be used with caution in patients with impaired liver or kidney function, metformin, a biguanide, has become the most commonly used agent for type 2 diabetes in children and teenagers. (wikipedia.org)
  • Metformin is usually the first-line medication used for treatment of type 2 diabetes. (wikipedia.org)
  • Segment
  • SGLT-2 is primarily expressed in the kidney on the epithelial cells lining the first segment of the proximal convoluted tubule. (wikipedia.org)
  • hyperglycemia
  • Persons with type 2 diabetes have an increased incidence of UTIs which may be related to hyperglycemia, glycosuria and/or neurogenic bladder associated with diabetes. (diabetesincontrol.com)
  • With the exception of the glucagon-like peptide 1 analogs and the thiazolidinediones ( 2 ), other antidiabetic medications lose their effectiveness to control hyperglycemia over time, partially due to the progressive decline of β-cell function ( 2 - 4 ). (diabetesjournals.org)
  • cardiovascular
  • People with T2D have a 2-3 times greater risk of heart failure and are at an increased risk of having a heart attack or stroke, and some 50 per cent of deaths in people with T2D are caused by cardiovascular disease. (business-standard.com)
  • With new medications regularly coming to the market for the treatment of type 2 diabetes, the question of medication selection revolves around hemoglobin A1C reduction potential, risk of cardiovascular adverse effects, and risk of hypoglycemia. (uspharmacist.com)
  • Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. (springer.com)
  • Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. (springer.com)
  • It is the only oral medicine for type 2 diabetes that has been shown to reduce the risk of cardiovascular death. (wikipedia.org)
  • India
  • This data generated from a broad population of patients with type 2 diabetes exemplifies the clinical study results providing confidence to the broader physician community on the role of SGLT-2i class in diabetes care," AstraZeneca India, Head of Medical Affairs Anilda D'souza said. (business-standard.com)
  • class
  • The newer SGLT2i class of medicines represents a significant advancement in treatment of type 2 diabetes. (business-standard.com)
  • Real-world data from this study provides striking evidence that the newer SGLT-2i class of medicines cuts the rate of hospitalisation for heart failure and death by approximately half. (business-standard.com)
  • Bruce Cooper, Vice President and Head of Global Medical Affairs at AstraZeneca , said: "Real-world data from this study provide striking evidence that the newer SGLT-2i class of medicines cuts the rate of hospitalisations for heart failure and death by approximately half. (diabetes.co.uk)
  • Gliflozins are a class of drugs in the treatment of type 2 diabetes (T2D). (wikipedia.org)
  • primarily
  • The compound is poorly absorbed from the gastrointestinal tract and inhibits both SGLT1 (primarily found in the gastrointestinal tract) and SGLT2. (diabetesjournals.org)
  • Effects
  • Unfortunately, COX-2 also has some important effects in protecting blood vessels. (diabetesselfmanagement.com)
  • CVD-REAL is the first study to observe these effects of SGLT-2i treatment in a much broader and lower risk group of type 2 diabetes patients than previously evaluated in clinical trials . (diabetes.co.uk)
  • risk
  • SGLT-2 drugs were shown to lower the combined risk of hospitalisation for heart failure and death from any cause by 46 per cent. (diabetes.co.uk)
  • There is low risk of clinically relevant pharmacokinetics drug interactions because of the metabolic pathway of SGLT2. (wikipedia.org)
  • serum
  • Patients, identified through electronic medical records, were included if they had a type 2 diabetes diagnosis and available serum creatinine data. (diabetesincontrol.com)
  • 2. Serum creatinine criteria (i.e. increase serum creatinine by ≥ 0.3 mg/dL within 48h or increase in serum creatinine by ≥ 1.5 times baseline value in the prior 7 days). (diabetesincontrol.com)
  • medicines
  • Now a study of more than 300,000 people across six countries has demonstrated significant health benefits of the oral medication compared to other medicines used to treat type 2 diabetes . (diabetes.co.uk)
  • patients
  • All trials with a duration of treatment ≥12 weeks, enrolling patients with type 2 diabetes, comparing a SGLT2i with placebo or other comparators were included. (springer.com)
  • White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. (springer.com)
  • Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. (springer.com)
  • Patients were above 20 and had type 2 diabetes for atlas 12 weeks. (wikipedia.org)
  • clinical
  • 5 , 6 Additionally, at least one company is developing anti-sense technology to reduce the expression of SGLT2 and one molecule, ISIS-SGLT2 Rx , is currently in phase 1 clinical trials. (diabetesjournals.org)